Your doctor orders a liver function test and the results show that your SGPT is out of range, 68 IU/L. The reference value for the test was 56. As you Google yourself into finding out that something terrible must be wrong, let us see what exactly this test measures, what it actually tells about your liver function and why it is important to know a little more before concluding anything drastic.
SGPT refers to Serum Glutamic-Pyruvic Transaminase, which is now known as Alanine Transaminase (ALT). ALT is one of the four enzymes included in a regular test of liver function and it is also considered to be the most liver-specific of them all. But why is it so?
ALT catalyses a reversible transamination reaction: it transfers the amino group from alanine to alpha-ketoglutarate, producing pyruvate and glutamate. This process is at the intersection of the metabolism of amino acids and the citric acid cycle and is hence referred to as a housekeeping enzyme of hepatic metabolism.
The reason why ALT is a unique enzyme specific to the liver is because of the enzyme distribution. ALT is abundant almost exclusively in the hepatocytes' cytoplasm. This enzyme is unlike SGOT (AST) that is found in the liver, heart, skeletal muscle, kidneys, and red blood cells. If there is any damage to the hepatocytes, then their cytoplasm will leak out into the blood stream, and ALT is the early warning sign for this leakage
ALT needs a cofactor called pyridoxal-5-phosphate (P5P). It is important to remember that P5P is the vitamin B6. This biochemical dependency on vitamin B6, has a direct implication for laboratory testing that is frequently overlooked in clinical practice, which is addressed in the methods section below.
The widely used reference range for ALT is 7 to 56 IU/L for adults, based on the IFCC kinetic method at 37 degrees Celsius. However, this is a population-derived range and several population-specific nuances apply, particularly in the Indian clinical context:
| Population | SGPT (ALT) IU/L | Clinical Note | Threshold for Investigation |
|---|---|---|---|
| Adult men | 7-56 IU/L | Higher due to greater muscle mass and metabolic activity | > 56 IU/L on repeat testing |
| Adult women | 7-45 IU/L | Lower physiological baseline; post-menopausal values may rise slightly | > 45 IU/L on repeat testing |
| Pregnancy | Slightly lower or normal in T1 and T2; mild rise acceptable in T3 | Significant elevation warrants urgent review for HELLP or obstetric cholestasis | > 2x ULN requires urgent evaluation |
| Adolescents | Slightly higher than adult range | Reflects higher metabolic turnover during growth | Interpret alongside clinical context |
| Lean MASLD risk (Indian adults) | Standard range applies; normal BMI does not exclude pathology | 33.7% of lean liver donors in India showed MASLD on biopsy | Any persistent elevation warrants investigation regardless of BMI |
Some hepatologists advocate for stricter sex-specific thresholds: ALT > 30 IU/L in men and > 19 IU/L in women as more sensitive cutoffs for early hepatic pathology, particularly for MASLD screening. These lower thresholds are not yet universally adopted in India but are worth noting when interpreting borderline results.
The number on your report is only as reliable as the method used to produce it and the conditions under which the sample was collected. This is an area that rarely appears in patient-facing articles but directly affects clinical decision-making.
| Method | Principle | Key Advantage | Limitation / Caution |
|---|---|---|---|
| IFCC kinetic UV (37°C) | Measures rate of NADH oxidation in the coupled reaction with oxaloacetate and malate dehydrogenase | Gold standard; most accurate; used by most modern analysers | Without P5P activation, underestimates ALT in B6-deficient patients |
| IFCC with P5P activation | Adds pyridoxal-5-phosphate to saturate apoenzyme before measurement | Corrects for B6 deficiency; gives true ALT activity | Not universally offered; adds cost and complexity |
| DGKC kinetic method | Similar coupled reaction at 37°C but uses DGKC reagent specifications | Widely used in India; comparable to IFCC in most patient populations | Results not directly interchangeable with IFCC values; check your lab's method |
| Point-of-care (POC) devices | Reflectance photometry or electrochemical detection on dry-chemistry strips | Rapid turnaround; useful in primary care and field settings | Less precise; not suitable for monitoring small changes or borderline values |
Pre-analytical errors are an under-recognized source of false results:
Haemolysis: the primary pre-analytical interference. Haemolysis leads to release of ALT from red blood cells into the plasma, causing an erroneously elevated result. Highly haemolyzed samples must be excluded, and the test rerun on new samples. Most current analysers are able to detect haemolysis automatically; however, mild cases will go unnoticed..
Delayed separation: ALT is stable in serum for roughly 3 days when stored at 4 degrees Celsius. Significant delay between sample collection and centrifugation, or prolonged storage at room temperature, can cause enzyme degradation and falsely low results.
Vigorous exercise: Intense physical exertion within 24 hours of blood collection can transiently elevate ALT by up to 3 times the upper limit of normal in some individuals, particularly those with high muscle mass. Always ask patients if they have performed any exercise in the preceding 24 hours before considering pathology as the reason for raised values.
Lipemia: severe hyperlipidaemia will result in a turbid sample, interfering with spectrophotometric tests. Bichromatic measurement, which is used in most current analysers, is capable of eliminating lipemic interference in ALT results.
Vitamin B6 deficiency: in patients with renal failure on dialysis, alcohol abuse, pregnancy, or malabsorption syndromes, B6 deficiency is common. The standard IFCC method without P5P activation underestimates true ALT activity in these patients. If clinical suspicion of liver disease is high but ALT is unexpectedly normal, B6-deficient states should be considered.
A raised SGPT almost always indicates hepatocyte injury or increased hepatocyte turnover. The degree of elevation and the clinical context narrow the differential significantly:
MASLD (metabolic dysfunction-associated steatotic liver disease): the most common etiology for raised ALT levels in the Indian population. A systematic analysis suggested that the prevalence of MASLD in the adult Indian population was around 38.6%. Importantly, even lean MASLD is common in India. The normal body mass index does not rule out fatty liver. The elevated ALT level is one to three times the upper limit of normal in MASLD.
Acute viral hepatitis (A, B, C, E): typically results in very high ALT levels, which could be ten to hundred times the upper limit of normal. Hepatitis E virus infection is common in India and remains underdiagnosed. Elevated ALT is characteristic of viral hepatitis rather than alcohol consumption.
Drug-induced liver injury (DILI): Antitubercular treatment is a major cause of drug-induced liver toxicity in India because of its high prevalence. Isoniazid, rifampicin, and pyrazinamide are hepatotoxic agents, and it is necessary to monitor transaminase levels during antitubercular treatment. Other causes of DILI include paracetamol overdose, statins, antifungal medications, and various traditional medications. Patients tend not to report use of traditional medicines unless directly questioned.
Alcoholic liver disease: Typically produces an AST-dominant pattern (De Ritis ratio > 2), with ALT disproportionately lower than AST. A mild-to-moderate ALT elevation with a significantly higher SGOT and an elevated GGT is the classic triad.
Autoimmune hepatitis: Can present with ALT elevations ranging from mild to severe, often in young to middle-aged women. Should be considered when viral and metabolic causes are excluded, particularly if IgG is elevated.
Thyroid disease: Hypothyroidism and hyperthyroidism can both cause mild transaminase elevation through indirect mechanisms. Thyroid function testing is warranted in unexplained mild ALT elevation without an obvious hepatic cause.
Vigorous exercise and rhabdomyolysis: As noted above, exercise can transiently raise ALT. Frank rhabdomyolysis produces markedly elevated ALT alongside a disproportionately elevated SGOT and creatine kinase.
As a biochemist, the distinction I keep returning to is cellular compartmentalisation of the enzymes. ALT is a cytoplasmic enzyme which is found at a very high concentration specifically in liver cells. SGOT (AST), on the other hand, can be found either in the cytoplasm or the mitochondria of various tissues such as the heart, skeletal muscles, kidney, and red blood cells.
There are two implications of this comparison in clinical scenarios. Firstly, elevated levels of just ALT indicate a liver problem while elevated levels of just SGOT may suggest problems in the liver, heart, skeletal muscles or red blood cells. Secondly, the presence of both enzymes indicates something based on the ratio between them. If the ALT levels are higher than the SGOT levels (a ratio less than 1), it shows that there is damage to liver cells causing cytoplasmic contents to leak; early MASLD or viral hepatitis. On the contrary, the damage is to the mitochondria, indicating alcoholic hepatitis or advanced cirrhosis.
That's why SGPT/ALT is the more specific enzyme and why it is usually the first enzyme to be ordered in patients with liver disease. SGOT/ AST adds value through the ratio, not in isolation.
As a biochemist, the comparison that I keep coming back to is the compartmentalization of the enzymes. ALT is a cytoplasmic enzyme which is found at a very high concentration specifically in liver cells. SGOT (AST), on the other hand, can be found either in the cytoplasm or the mitochondria of various tissues such as the heart, skeletal muscles, kidney, and red blood cells.
There are two implications of this comparison in clinical scenarios. Firstly, elevated levels of just ALT indicate a liver problem while elevated levels of just SGOT may suggest problems in the liver, heart, skeletal muscles or red blood cells. Secondly, the presence of both enzymes indicates something based on the ratio between them. If the ALT levels are higher than the SGOT levels (a ratio less than 1), it shows that there is damage to liver cells causing cytoplasmic contents to leak; early MASLD or viral hepatitis. On the contrary, the damage is to the mitochondria, indicating alcoholic hepatitis or advanced cirrhosis.
1 to 3 times ULN (up to approximately 168 IU/L): mild elevation. Rule out recent exercise, alcohol use, new medications, and herbal preparations. Repeat in 4 to 8 weeks. If persistent, investigate for MASLD, viral hepatitis serology, and thyroid function.
3 to 10 times ULN (approximately 168 to 560 IU/L): moderate elevation. Warrants prompt investigation. Order viral hepatitis panel (HBsAg, anti-HCV, anti-HAV IgM, anti-HEV IgM), abdominal ultrasound, and full medication review including traditional medicines.
More than 10 times ULN (above 560 IU/L): marked elevation indicating acute hepatocellular injury. Causes include acute viral hepatitis, ischaemic hepatitis (shock liver), severe DILI including paracetamol toxicity, and acute autoimmune hepatitis. Requires urgent evaluation.
More than 1000 IU/L: seen in acute hepatitis A or E, ischaemic hepatitis, and paracetamol overdose. This is a medical emergency.
Note: A normal SGPT does not exclude significant liver disease. In compensated cirrhosis, the functional hepatocyte mass is so reduced that little enzyme remains to leak. A normal ALT with low albumin, elevated bilirubin, or a prolonged PT/INR is a more ominous picture than an isolated ALT of 80.
SGPT greater than 10 times the upper limit of normal on any report
Jaundice: yellowing of the skin or whites of the eyes
Dark (tea-coloured) urine or pale, clay-coloured stools
SGPT rising on serial testing despite stopping the suspected causative drug
Any SGPT elevation accompanied by a falling albumin or rising bilirubin
Unexplained bruising or prolonged bleeding from minor cuts
Confusion or unusual sleepiness in a patient with known liver disease
Any significant SGPT elevation in a pregnant patient, especially with itching or jaundice
SGPT elevation in a patient on antitubercular therapy: stop ATT and seek urgent hepatology review
Patients with type 2 diabetes, obesity, or metabolic syndrome should have annual SGPT testing even without symptoms, given India's high silent MASLD prevalence. Patients on ATT, statins, anticonvulsants, or antifungals require periodic transaminase monitoring per prescribing guidelines. Patients with renal failure on dialysis or alcohol use disorder may have falsely low SGPT due to vitamin B6 deficiency; inform the clinician ordering the test so that P5P-activated ALT measurement can be requested if available. Anyone using herbal or Ayurvedic preparations alongside conventional medications must disclose this to their treating clinician.
A single mild elevation warrants attention, not alarm. Rule out heavy exercise, alcohol use, or new medications in the preceding 48 hours. If the elevation persists on repeat testing after 4 to 6 weeks without an obvious transient cause, further evaluation for MASLD or viral hepatitis is appropriate.
Prolonged fasting can cause mild transient ALT elevation through fatty acid mobilisation and hepatic stress. A standard overnight fast of 8 to 10 hours for an LFT panel does not significantly affect SGPT. Extended fasting beyond 24 hours can produce a small but measurable rise.
A normal SGPT does not exclude liver disease. Compensated cirrhosis, early MASLD, and chronic hepatitis B or C can all present with normal or near-normal SGPT values. Liver synthetic function markers including albumin, bilirubin, and prothrombin time are more reliable indicators of how well the liver is actually working.
In MASLD, weight loss of 5 to 10 percent of body weight is associated with meaningful reductions in ALT and improvements in liver histology. This is one of the most evidence-based interventions for fatty liver disease. However, ALT normalisation should be confirmed on serial testing and does not necessarily mean complete resolution of underlying hepatic changes.
Lala, V., Zubair, M., & Minter, D. A. (2023). Liver function tests. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482489/
Prabhu, A., et al. (2022). Prevalence of non-alcoholic fatty liver disease in India: A systematic review and meta-analysis. Journal of Clinical and Experimental Hepatology, 12(3), 818-829. https://doi.org/10.1016/j.jceh.2021.11.010
Nayak, N. C., et al. (2024). Navigating disease management: A comprehensive review of the De Ritis ratio in clinical medicine. Cureus, 16(8), e66497. https://doi.org/10.7759/cureus.66497
IFCC Scientific Division. (2002). IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Clinical Chemistry and Laboratory Medicine, 40(7), 725-733. https://doi.org/10.1515/CCLM.2002.127
MSM